Could a Two-Drug HIV pill be enough for transgender women?
NCT ID NCT06967753
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 29 times
Summary
This study tests if switching to a two-drug combination (dolutegravir and lamivudine) can safely keep HIV under control in transgender women who are already on a stable three-drug regimen. About 50 participants will take the new pills for 48 weeks. The goal is to see if the simpler treatment works just as well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital General de Agudos Dr. Juan A. Fernández, Infectious Diseases Division
RECRUITINGBuenos Aires, Buenos Aires F.D., 1425, Argentina
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.